Rhabdomyolysis is an uncommon event during trabectedin treatment. Multivariate analyses did not show any potential factor that could be predictive or represent a significantly higher risk of developing rhabdomyolysis. Nevertheless, close patient monitoring and adherence to drug administration guidelines may help to limit the incidence of this event.
No takes yet. Share an insight, caveat, or question.
Grosso et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: